跳至主要内容
临床试验/NL-OMON47479
NL-OMON47479已完成不适用

CareMore study 1: prognostic value of HER2-positive circulating tumor cells in metastatic breast cancer patients treated with aromatase inhibitors (CareMore-AI study) - CareMore-AI

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 300 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational invasive

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Female patient with metastatic breast cancer
  • - Age >= 18 years
  • - Written informed consent

排除标准

  • - Adjuvant chemotherapy within 6 months prior to treatment start
  • - Other anticancer chemotherapy, use of biological response modifiers, or
  • immunotherapy within two weeks prior to treatment start. Hormonal antitumor
  • treatment within one week prior to treatment start.
  • - Serious illness or medical unstable condition prohibiting adequate treatment
  • and follow-up

研究者

相似试验